Labshake search
Citations for Tocris :
251 - 300 of 1961 citations for 6 METHYL 4 4 NITRO PHENYL 2 OXO 1 2 3 4 TETRAHYDRO PYRIMIDINE 5 CARBOXYLIC ACID ETHYL ESTER since 2019
Citations are collected from bioRxiv only, the total number of publications could be much larger.
-
bioRxiv - Neuroscience 2019Quote: ... To block NMDA receptors we used D- (-)-2-Amino-5-phosphonopentanoic acid (D-AP5, Tocris, 10 μM final concentration). To block glycinergic inhibition ...
-
bioRxiv - Neuroscience 2020Quote: ... 20 μM 6,7-dinitroquinoxaline-2,3-dione (DNQX) and 20 μM D-(-)-2-amino-5-phosphopentanoic acid (D-AP5) (Tocris Bioscience) to block glycine- ...
-
bioRxiv - Cell Biology 2020Quote: ... cells were treated with 50 nM VU0364739 inhibitor (N-[2-[1-(3-Fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl]-2-naphthalenecarboxamide) (Lavieri et al., 2010) for 16 h (Tocris Bioscience). For lysosomal inhibition ...
-
bioRxiv - Neuroscience 2023Quote: ... either alone or with 10 µM 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX, Tocris). Neurons were fixed with 4% PFA and 4% sucrose in PBS for 10 minutes at room temperature ...
-
bioRxiv - Neuroscience 2021Quote: ... and (+)-Bicuculline (CAS #485-49-4) were purchased from Tocris. H-89 (CAS #130964-39-5) ...
-
bioRxiv - Neuroscience 2021Quote: ... Quinpirole 0.25-4 mg/L diluted in H2O (Tocris #1061) was administered by immersion for 1 hour.
-
bioRxiv - Neuroscience 2022Quote: ... 100 μM of CGP 54626 (Tocris, CAS: 149184-21-4) and 250 μM of picrotoxin (Sigma-Aldrich ...
-
bioRxiv - Neuroscience 2023Quote: ... 0,2 4-methoxy-7-nitroindolinyl (MNI)-caged glutamate (Tocris Bioscience), 0,005 CPP [()-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid] (NMDA receptors antagonist ...
-
bioRxiv - Neuroscience 2024Quote: ... NE-100 (CAS#:149409-57-4) was purchased from Tocris Bioscience (Ellisville MO) ...
-
bioRxiv - Cancer Biology 2024Quote: ... AKTi-1/2 (Tocris), MK-2206 (VWR) ...
-
bioRxiv - Neuroscience 2020Quote: ... During BQA experiments the ACSF solution contained the following substances: 10 μM D-(−)-2-Amino-5-phosphonopentanoic acid (D-AP5) (Tocris), 10 μM 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX ...
-
bioRxiv - Neuroscience 2022Quote: ... 12-well plates at 3-4 × 105 cells/well in mTeSR1 with 10 µM rho-kinase inhibitor (Y-27632; Tocris, 1254). Medium without the inhibitor was replaced daily until the cells reach 80-100% confluency ...
-
bioRxiv - Biochemistry 2022Quote: ... Positive clones were analyzed by Sanger sequencing with primers #3 and #4 (Integrated DNA Technologies, Supplementary Table S5) and degradation upon dTAG-13 (Tocris, 6605) treatment was confirmed by Western Blot by a-Chaf1a antibody (65) ...
-
bioRxiv - Bioengineering 2021Quote: ... supplemented with FGF-2 (20 ng ml−1), Activin-A (50 ng ml−1), BMP-4 (10 ng ml−1, R&D) and LY294002 (10 mM Tocris). Media was changed again after 42 hours to CDM-BSA supplemented with FGF-2 (8 ng ml−1) ...
-
bioRxiv - Cell Biology 2021Quote: ... flow cytometer, and the fractions of stained cells were quantified using FloJo 10.6, with Staurosporine (4 h, 5 μM) (Tocris, 1285) used as a positive control for cell death and to help establish gating of the sorted cells.
-
bioRxiv - Neuroscience 2021Quote: ... 20 μM of 2,3-dihydroxy 6-nitro-7-sulfamoyl-benzoquinoxaline-2,3-dione (NBQX, 1044, Tocris Bioscience, UK), 25 μM of d-(-)-2-amino-5-phosphonopentanoic acid (D-AP5 ...
-
bioRxiv - Neuroscience 2019Quote: ... Cells were split 12–30 h after transfection and plated on glass coverslips in the presence of 50 μM NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide; Tocris Bioscience) to avoid AMPAR-mediated toxicity ...
-
bioRxiv - Neuroscience 2024Quote: ... All networks received a 20-min 50 µM 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX, in DMSO; Tocris, #0373) treatment on top of that ...
-
bioRxiv - Cell Biology 2020Quote: Oxotremorin-M (Oxo-M, Tocris Bioscience, Bristol, UK) was prepared in a 10mM stock solution in water and diluted to 10 µM in extracellular solution ...
-
bioRxiv - Neuroscience 2020Quote: ... and the aquaporin-4 channel inhibitor TGN-020 (Tocris; 100 μM) were co-applied (n=16) ...
-
bioRxiv - Physiology 2021Quote: ... and/or 4) 100 nM ONO-8130 (Tocris Bioscience, Bristol, UK). In the latter two conditions ...
-
bioRxiv - Neuroscience 2023Quote: ... 50 µM CGP54626 Hydrochloride (1088/10, TOCRIS, CAS 149184-21-4), 200 µM (low dose ...
-
bioRxiv - Neuroscience 2021Quote: ... NMDA receptor (R) dependency was tested by application of an NMDAR antagonist (APV 50 µM, DL-2-Amino-5-phosphonopentanoic acid, Tocris, Germany) in the bath solution ...
-
bioRxiv - Neuroscience 2022Quote: ... containing 10 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 50 μM D,L-2-amino-5-phosphonovaleric acid (AP5) (both from Tocris, Bristol, UK) to block recurrent glutamatergic signaling.
-
bioRxiv - Neuroscience 2023Quote: ... The following compounds were added to raCSF as indicated in the Results section: D-(-)-2-Amino-5-phosphonopentanoic acid (D-APV, 100 μM dissolved in H2O; Tocris Bioscience), (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine maleate (MK-801 ...
-
bioRxiv - Neuroscience 2022Quote: ... Intervet AB, Sweden), PCP (phencyclidine hydrochloride, 5 mg/kg, Lipomed AG, Switzerland) or amphetamine (d-amphetamine hydrochloride, 4 mg/kg, Tocris, UK) and recorded for another 60-120 minutes ...
-
bioRxiv - Neuroscience 2019Quote: ... and NMDAR EPSCs were then isolated by addition of the AMPAR antagonist 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX, 10 µM; Tocris, Cat# 1044). NMDAR EPSCs were confirmed by addition of the NMDAR antagonist D,L-APV (20 µM ...
-
bioRxiv - Neuroscience 2020Quote: ... to allow outside-out patch recording and 30 μM 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX; Tocris, Cat#1044) was added to media post-transfection to avoid AMPAR-mediated toxicity.
-
bioRxiv - Neuroscience 2022Quote: ... Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-[1,3]dioxocino[6,5-d] pyrimidine-4,7,10,11,12-pentol (Tetrodotoxin: TTX) were purchased from Tocris Bioscience ...
-
Safety and efficacy of C9ORF72-repeat RNA nuclear export inhibition in amyotrophic lateral sclerosisbioRxiv - Systems Biology 2021Quote: ... supplemented with SMAD inhibitors (DMH-1 2 µM; SB431542-10 µM and CHIR99021 3 µM [ [Tocris]). The medium was changed every day for 6 days ...
-
bioRxiv - Neuroscience 2021Quote: ... 3-((±)2-carboxypiperazin-4yl) propyl-1-phosphate (CPP, NMDA receptor antagonist, 20 μM; Tocris Bioscience, UK) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX ...
-
bioRxiv - Neuroscience 2020Quote: ... containing 10 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 50 μM D,L-2-amino-5-phosphonovaleric acid (AP5) to block glutamatergic signaling (both from Tocris, Bristol, UK). Experiments involving tetrodotoxin (TTX ...
-
bioRxiv - Neuroscience 2020Quote: ... MNI-caged L-glutamate (4-methoxy-7-nitroindolinyl-caged L-glutamate, Tocris) was uncaged with a train of 8–10 ms laser pulses (under the objective ...
-
bioRxiv - Neuroscience 2020Quote: ... Cultures treated for 4 h with NMDA (50 μg/ml; Tocris #0114) and cultures incubated for 2 h with PI after fixation (referred to as ‘post-fixation’ ...
-
bioRxiv - Neuroscience 2022Quote: ... Cultures treated for 4 h with NMDA (50 μg/ml; #0114 Tocris) served as positive controls in these experiments ...
-
bioRxiv - Neuroscience 2023Quote: ... we tested effects of an inhibitor (the spider toxin GsMTX 4; Tocris #4912 stock 50 μM in DMSO and the Piezo1 channel activator Yoda1 (Tocris 6586 10 and 20 uM ...
-
bioRxiv - Bioengineering 2024Quote: ... CDM was supplemented with 4 μM CHIR99021 (Tocris Bioscience, cat. no. 4423), and from day 2 to day 4 ...
-
bioRxiv - Neuroscience 2023Quote: ... Drug treatments correspond to a single dose of cocaine hydrochloride at 20 mg/kg (Medisca, cat# 53-21-4, Canada) or D-amphetamine sulfate at 5 mg/kg (Tocris, 2813, UK) at doses known to increase locomotion87 ...
-
bioRxiv - Cell Biology 2021Quote: ... or the AMPA-iGluR specific inhibitor 2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX, cat. num. 373, Tocris). Drugs were dissolved in ESC complete media (no 2i ...
-
bioRxiv - Neuroscience 2019Quote: ... 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (“NBQX”, 100 mM in DMSO, Tocris Cat No 0373); D-2-amino-5-phosphonovalerate (“D-AP5” ...
-
bioRxiv - Neuroscience 2020Quote: ... and D-2-amino-5-phosphonovalerate (APV, 25 µM, Tocris) in order to block synaptic transmission and ensure that the observed events were due to the stimulation only ...
-
bioRxiv - Neuroscience 2023Quote: ... Step 2: synaptic blockers (50µm DL-AP-5 (Tocris #0105), 40µm L-AP4 (Tocris #0103) ...
-
bioRxiv - Neuroscience 2023Quote: ... 20 L-AP4 (Alomone Labs) and 2-5 ACET (Tocris) (Park et al. ...
-
bioRxiv - Neuroscience 2022Quote: ... and 2 μM DMH-1 (Tocris) for 6 d ...
-
bioRxiv - Neuroscience 2019Quote: ... 4-methoxy-7-nitroindolinyl-caged L-glutamate (MNI-glutamate) were purchased from Tocris Cookson (UK) ...
-
bioRxiv - Immunology 2021Quote: ... The non-selective MIF family cytokine inhibitor 4-IPP was obtained from Tocris Bioscience.
-
bioRxiv - Cancer Biology 2023Quote: ... The N2/B27 medium was supplemented with 4 µM Dorsomorphin (Tocris, Cat # 3039) and 10 µM SB431542 (Tocris ...
-
bioRxiv - Neuroscience 2023Quote: ... MNI-glutamate (4 methoxy-7-nitroindolinyl caged L-glutamate) was purchased from Tocris Bioscience ...
-
bioRxiv - Bioengineering 2024Quote: ... supplemented with 50 ng/mL bone morphogenetic protein 4 (BMP4; Tocris; 314-BP) and 100 ng/mL activin A (Tocris ...
-
bioRxiv - Bioengineering 2024Quote: ... supplemented with 50 ng/mL bone morphogenetic protein 4 (BMP4; Tocris; 314-BP) and 100 ng/mL activin A (Tocris ...